Breaking News

Crucell Resolves Issues at South Korea Plant

Crucell NV can resume selling its vaccine Quinvaxem to United Nations agencies, after investigations by the World Health Organization showed the manufacturing problems at Crucell’s plant in South Korea were resolved.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Crucell NV can resume selling its vaccine Quinvaxem to United Nations agencies, after investigations by the World Health Organization showed the manufacturing problems at Crucell’s plant in South Korea were resolved. Crucell suspended production due to sterility issues at the plant and stopped shipments of two children’s vaccines, including Quinvaxem.

The manufacturing problems resulted in a loss for the company in 2010 and put on hold Johnson & Johnson’s $2.4 billion bid to takeover the company. J&J’s bid expires February 16th; the company currently holds about 18% of Crucell shares.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters